東華大學圖書館 |

Would Chinese Herbal Medicines Influence with the Androgen Receptor in Prostate Cancer? Investigations on In Vitro and In Vivo Models.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Would Chinese Herbal Medicines Influence with the Androgen Receptor in Prostate Cancer? Investigations on In Vitro and In Vivo Models./
作者:	Zhang, Zhenbiao.
面頁冊數:	1 online resource (178 pages)
附註:	Source: Dissertations Abstracts International, Volume: 82-11, Section: B.
Contained By:	Dissertations Abstracts International82-11B.
標題:	Medicine. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28506412click for full text (PQDT)
ISBN:	9798708721624

Would Chinese Herbal Medicines Influence with the Androgen Receptor in Prostate Cancer? Investigations on In Vitro and In Vivo Models.
Zhang, Zhenbiao.

Would Chinese Herbal Medicines Influence with the Androgen Receptor in Prostate Cancer? Investigations on In Vitro and In Vivo Models. - 1 online resource (178 pages)

Source: Dissertations Abstracts International, Volume: 82-11, Section: B.

Thesis (Ph.D.)--The Chinese University of Hong Kong (Hong Kong), 2020.

Includes bibliographical references

Prostate cancer (PCa) is the second leading cause of male mortality after lung cancer in many Western countries. Although androgen deprivation therapy (ADT) plays a central role in the management of PCa, most patients inevitably develop castrationresistant prostate cancer (CRPC) after long-term treatment with ADT. Many patients seek other alternative therapeutic strategies, such as Chinese herbal medicine (CHM), to alleviate the side effects associated with conventional anti-PCa therapy and improve the quality of life. However, concerns have been raised about the potential herb-drug interaction between CHMs containing phytoandrogens and androgen receptor (AR) antagonists such as abiraterone (ABI). In this study, we aimed to investigate the effects of selected CHMs on AR expression and their combination with ABI on tumor growth using in vitro and in vivo experimental models. A total of 21 CHMs were selected for this study. The 21 selected CHMs were extracted with 70% aqueous ethanol. The anti-proliferative effects and AR-related protein expression activities of the 21 extracts of CHMs were investigated in LNCaP and 22Rv1 cell lines, while the effects of these CHMs on tumor growth and AR expressions evaluated on the 22Rv1 subcutaneous PCa animal model. Then 3 extracts of CHMs including Epimedii Folium (EF, 淫羊藿), Codonopsis Radix (CNR, 黨參) and Astragali Radix (AGR, 黃芪) were investigated for their interaction with ABI on tumor growth and AR expressions, as well as the protein pathways (PI3K/AKT signaling and Rb/E2F signaling) using two 22Rv1 xenograft PCa animal models. Finally, the pharmacokinetics of ABI was evaluated in the plasmas of rats when combined with EF, CNR or AGR. The results showed that treatment with Ophiopogonis Radix (OR, 麥冬), EF and CNR could substantially accentuate the cell proliferation and AR protein expression in vitro, while Dendrobii Caulis (DC, 石斛), Chuanxiong Rhizoma (CXR, 川芎), Bruceae Fructus (BF, 鴉膽子 ) and AGR treatment significantly suppressed the cell proliferation and AR protein expression. In addition, treatment with Cistanches Herba (CCH, 肉蓯蓉), EF and CNR dramatically promoted the tumor growth by activating the AR signaling, whereas CXR, BF and AGR administration could significantly exert the anti-tumor effects through suppressing the AR signaling. Further investigation showed that EF or CNR co-treated with ABI significantly repressed the anti-tumor effects of ABI by activating the PI3K/AKT signaling and Rb/E2F signaling, indicating that EF and CNR could adversely affect the therapeutic efficacy of ABI in PCa. On the other hand, co-treatment with AGR could significantly enhance the therapeutic efficacy of ABI by suppressing the PI3K/AKT signaling and Rb/E2F signaling. Finally, the pharmacokinetic study revealed that EF could reduce the plasma concentrations of ABI to attenuate its therapeutic effects, while CNR was found to curtail the treatment duration of ABI to inhibit its anti-cancer effects. On the contrary, cotreatment with AGR and ABI was found to significantly improve the plasma concentrations of ABI, indicating that the enhanced therapeutic effects of the combination of AGR and ABI. Taken together, our study provided experimental evidence that some yang tonifying Chinese herbs could activate the AR activity in PCa experimental models, implying that cautions should be exercised when prescribing this category of CHMs in PCa patients.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798708721624Subjects--Topical Terms:

641104
Medicine.
Subjects--Index Terms:

Prostate cancerIndex Terms--Genre/Form:

542853
Electronic books.

Would Chinese Herbal Medicines Influence with the Androgen Receptor in Prostate Cancer? Investigations on In Vitro and In Vivo Models.
LDR:04812nmm a2200349K 4500 001 2355342
005 20230512095449.5
006 m o d
007 cr mn ---uuuuu
008 241011s2020 xx obm 000 0 eng d
020 $a 9798708721624
035 $a (MiAaPQ)AAI28506412
035 $a AAI28506412
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Zhang, Zhenbiao. $3 3695753
245 1 0 $a Would Chinese Herbal Medicines Influence with the Androgen Receptor in Prostate Cancer? Investigations on In Vitro and In Vivo Models.
264 0 $c 2020
300 $a 1 online resource (178 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 82-11, Section: B.
502 $a Thesis (Ph.D.)--The Chinese University of Hong Kong (Hong Kong), 2020.
504 $a Includes bibliographical references
520 $a Prostate cancer (PCa) is the second leading cause of male mortality after lung cancer in many Western countries. Although androgen deprivation therapy (ADT) plays a central role in the management of PCa, most patients inevitably develop castrationresistant prostate cancer (CRPC) after long-term treatment with ADT. Many patients seek other alternative therapeutic strategies, such as Chinese herbal medicine (CHM), to alleviate the side effects associated with conventional anti-PCa therapy and improve the quality of life. However, concerns have been raised about the potential herb-drug interaction between CHMs containing phytoandrogens and androgen receptor (AR) antagonists such as abiraterone (ABI). In this study, we aimed to investigate the effects of selected CHMs on AR expression and their combination with ABI on tumor growth using in vitro and in vivo experimental models. A total of 21 CHMs were selected for this study. The 21 selected CHMs were extracted with 70% aqueous ethanol. The anti-proliferative effects and AR-related protein expression activities of the 21 extracts of CHMs were investigated in LNCaP and 22Rv1 cell lines, while the effects of these CHMs on tumor growth and AR expressions evaluated on the 22Rv1 subcutaneous PCa animal model. Then 3 extracts of CHMs including Epimedii Folium (EF, 淫羊藿), Codonopsis Radix (CNR, 黨參) and Astragali Radix (AGR, 黃芪) were investigated for their interaction with ABI on tumor growth and AR expressions, as well as the protein pathways (PI3K/AKT signaling and Rb/E2F signaling) using two 22Rv1 xenograft PCa animal models. Finally, the pharmacokinetics of ABI was evaluated in the plasmas of rats when combined with EF, CNR or AGR. The results showed that treatment with Ophiopogonis Radix (OR, 麥冬), EF and CNR could substantially accentuate the cell proliferation and AR protein expression in vitro, while Dendrobii Caulis (DC, 石斛), Chuanxiong Rhizoma (CXR, 川芎), Bruceae Fructus (BF, 鴉膽子 ) and AGR treatment significantly suppressed the cell proliferation and AR protein expression. In addition, treatment with Cistanches Herba (CCH, 肉蓯蓉), EF and CNR dramatically promoted the tumor growth by activating the AR signaling, whereas CXR, BF and AGR administration could significantly exert the anti-tumor effects through suppressing the AR signaling. Further investigation showed that EF or CNR co-treated with ABI significantly repressed the anti-tumor effects of ABI by activating the PI3K/AKT signaling and Rb/E2F signaling, indicating that EF and CNR could adversely affect the therapeutic efficacy of ABI in PCa. On the other hand, co-treatment with AGR could significantly enhance the therapeutic efficacy of ABI by suppressing the PI3K/AKT signaling and Rb/E2F signaling. Finally, the pharmacokinetic study revealed that EF could reduce the plasma concentrations of ABI to attenuate its therapeutic effects, while CNR was found to curtail the treatment duration of ABI to inhibit its anti-cancer effects. On the contrary, cotreatment with AGR and ABI was found to significantly improve the plasma concentrations of ABI, indicating that the enhanced therapeutic effects of the combination of AGR and ABI. Taken together, our study provided experimental evidence that some yang tonifying Chinese herbs could activate the AR activity in PCa experimental models, implying that cautions should be exercised when prescribing this category of CHMs in PCa patients.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Medicine. $3 641104
650 4 $a Southeast Asian studies. $3 3344898
653 $a Prostate cancer
653 $a Androgen deprivation therapy
653 $a Pharmacokinetics
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0222
690 $a 0564
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a The Chinese University of Hong Kong (Hong Kong). $3 1017547
773 0 $t Dissertations Abstracts International $g 82-11B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28506412 $z click for full text (PQDT)